Valuation : Izotropic Corporation

Market Cap 11.99M 10.32M 9.71M 8.87M 16.59M 1.13B 16.63M 115M 44.5M 581M 45.01M 44.03M 1.87B P/E 2027 *
-
P/E 2028 * -
Enterprise Value 11.99M 10.32M 9.71M 8.87M 16.59M 1.13B 16.63M 115M 44.5M 581M 45.01M 44.03M 1.87B EV / Sales 2027 *
2.4x
EV / Sales 2028 * 1.2x
Free-Float
92.14%
Yield 2027 *
-
Yield 2028 * -
1 week-2.08%
1 month-7.84%
3 months-14.55%
6 months+4.44%
Current year-16.07%
1 week 0.22
Extreme 0.215
0.24
1 month 0.21
Extreme 0.21
0.26
Current year 0.19
Extreme 0.19
0.33
1 year 0.19
Extreme 0.19
0.49
3 years 0.04
Extreme 0.035
0.49
5 years 0.04
Extreme 0.035
1.24
10 years 0.04
Extreme 0.035
1.56
Manager TitleAgeSince
Chief Executive Officer 73 2023-05-31
Director of Finance/CFO 75 2022-12-31
Chief Operating Officer - 2022-12-31
Director TitleAgeSince
Director/Board Member 73 2016-05-18
Director/Board Member 51 2017-05-21
Director/Board Member 71 2017-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/25 Option

Chief Financial Officer

100,000 0.1761%
9/18/25 Option

Chief Financial Officer

100,000 0.1761%
9/17/25 Sell

Chief Financial Officer

100,000 0.1761%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.08%-26.56%-16.07% 11.99M
+3.33%+2.86%-23.88%+1.56% 13.22B
-2.36%-4.13%+10.60%+8.67% 4.23B
+3.96%+3.48%-37.52%-54.42% 1.27B
-1.36%-1.81%-36.41%-40.71% 1.14B
-3.63%-4.16%+15.92%+76.05% 1.07B
-1.80%-0.34% - - 1.03B
-0.50%-2.68%-37.21% - 1.02B
-3.35%-6.37%+25.67%+100.16% 503M
+0.34%+1.01%+67.32% - 300M
Average -0.54%-1.69%-4.67%+10.75% 2.38B
Weighted average by Cap. +1.25%+0.30%-15.29%+3.41%

Financials

2027 *2028 *
Net sales 5M 4.3M 4.05M 3.7M 6.92M 472M 6.94M 47.83M 18.56M 242M 18.78M 18.37M 780M 10M 8.6M 8.1M 7.4M 13.84M 944M 13.87M 95.67M 37.12M 484M 37.55M 36.73M 1.56B
Net income 2.3M 1.98M 1.86M 1.7M 3.18M 217M 3.19M 22.01M 8.54M 111M 8.64M 8.45M 359M 6.23M 5.36M 5.04M 4.61M 8.62M 588M 8.64M 59.58M 23.12M 302M 23.39M 22.88M 972M
Net Debt - -
Logo Izotropic Corporation
Izotropic Corporation is a Canada-based medical device company. The Company is engaged in commercializing imaging-based products utilizing emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers. Its lzoView computed tomography (CT) Imaging System is intended to produce cross-sectional images of anatomy that can be imaged in the 30 cm aperture by computer reconstruction of x-ray transmission data for non-invasive visualization of tissue. The IzoView is for use in the non-invasive visualization of breast tissue, as an adjunct tool to mammography, by providing x-ray computer reconstructed images as an aid for qualified healthcare providers. The Company has not generated any revenue.
Employees
-
Date Price Change Volume
26-09-04 $0.2350 0.00% 33,000
26-09-03 $0.2350 +9.30% 15,017
26-09-02 $0.2150 0.00% 5,704
26-09-01 $0.2150 -8.51% 11,650
26-08-31 $0.2350 -2.08% 51,150

Quarterly revenue - Rate of surprise